


# Computer-aided predictions in drug research and development

Vladimir Poroikov, Prof. Dr.

Institute of Biomedical Chemistry

*119121, Moscow, Pogodinskaya str., 10 bldg. 8*


*E-mail: vladimir.poroikov@ibmc.msk.ru*



<http://glp-planet.com/>





# Drug Research and Development: From Idea to Pharmacy



Mohsa R.C., Greig N.H. Drug discovery and development: Role of basic biological research. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 2017, 3: 651-657.

## Drug Repositioning: Time, Costs, Risks estimates



Poroikov V., Druzhilovskiy D. Drug Repositioning: New Opportunities for Older Drugs. In: In Silico Drug Design, 1st Edition. Repurposing Techniques and Methodologies. Chapter 1. Editors: Kunal Roy. Elsevier, Academic Press, 2019, p. 3-17.



# How to increase the chances for development of new drugs?




*If any new drug exists that has been discovered without computations?*


## The Many Roles of Computation in Drug Discovery

William L. Jorgensen


SCIENCE VOL 303 19 MARCH 2004



### Target-Based Drug Design



### Network Pharmacology



### Ligand-Based Drug Design





# PASS 2019 version (launched in July, 2019)



Dmitry Filimonov

## Prediction of Activity Spectra for Substances

2019

30 Years Anniversary of PASS

SAR Base Information	1989	2019
Substances	9 314	1 025 468
Descriptors		106 816
Activity Types	114	8 054
Selected Activity Types		5 066
Average IAP	0.74	0.96

151 of 506 Possible Pharmacological Effects at Pa > Pi

0.967	0.004	Neuroprotector
0.788	0.004	Vasodilator, peripheral
0.775	0.003	Diuretic
0.745	0.004	Cardioprotectant
0.672	0.010	Analeptic
<b>0.644</b>	<b>0.005</b>	<b>Antihypertensive</b>
0.589	0.014	Immunostimulant
0.580	0.019	Immunomodulator (HIV)
0.609	0.050	Fibrinolytic
0.546	0.009	Skin irritation, inactive
0.544	0.008	Psychostimulant
0.511	0.015	Vasodilator, coronary

50 Substructure Descriptors: 0 new.

631 of 5066 Possible Activities  
 151 of 506 Possible Pharmacological Effects  
 434 of 4263 Possible Mechanisms of Action  
 43 of 64 Possible Toxic and Adverse Effects  
 15 of 159 Possible Antitargets  
 28 of 199 Possible Metabolism-Related Actions  
 21 of 102 Possible Gene Expression Regulation  
 9 of 76 Possible Transporters-Related Actions

> <name>  
perindopril

Burov Yu.V., Poroikov V.V., Korolchenko L.V. National system for registration and biological testing of chemical compounds: facilities for new drugs search. *Bulletin of the National Center for Biologically Active Compounds*, **1990**, No. 1, p.4-25 (Rus.).

Poroikov V.V., Filimonov D.A., Glorizova T.A., et al. Computer-aided prediction of biological activity spectra for organic compounds: the possibilities and limitations. *Russ. Chem. Bull.*, **2019**, 68 (12), 2143-2154. DOI: 10.1007/s11172-019-2683-0



# PASS 2019 version (launched in July, 2019)



Dmitry Filimonov

Understanding Chemical-Biological Interactions

## Prediction of Activity Spectra for Substances

2019

30 Years Anniversary of PASS

SAR Base Information	1989	2019
Substances	9 314	1 025 468
Descriptors		106 816
Activity Types	114	8 054
Selected Activity Types		5 066
Average IAP	0.74	0.96

151 of 506 Possible Pharmacological Effects

0.967	0.004	Neuroprotector
0.788	0.004	Vasodilator, periph
0.775	0.003	Diuretic
0.745	0.004	Cardioprotectant
0.672	0.010	Analeptic
0.644	0.005	Antihypertensive
0.589	0.014	Immunostimulant
0.580	0.019	Immun
0.609	0.050	Fibrin
0.546	0.009	Skin ir
0.544	0.008	Psych



Andreas Bender  
(University of Cambridge)

“One of the earliest and most widely used examples of data-mining target elucidation is the continuously curated and expanded Prediction of Activity Spectra for Substances (PASS) software, which was assimilated from the bioactivities of more than 270,000 compound-ligand pairs.”

Mervin L.H., ... , Bender A. *Journal of Cheminformatics*, 2015, 7: 51.

Burov Yu.V., Poroikov V.V., Korolchenko L.V. National system for registration and biological testing of chemical compounds: facilities for new drugs search. *Bulletin of the National Center for Biologically Active Compounds*, 1990, No. 1, p.4-25 (Rus.).

Poroikov V.V., Filimonov D.A., Glorizova T.A., et al. Computer-aided prediction of biological activity spectra for organic compounds: the possibilities and limitations. *Russ. Chem. Bull.*, 2019, 68 (12), 2143-2154. DOI: 10.1007/s11172-019-2683-0



# Important remarks regarding the starting point of this project (seventies – eighties of the XX century)



Chemical compounds were synthesized by different chemists, in different institutions, for different purposes.



- Significant heterogeneity of chemical classes of the compounds submitted for the state registration.




Most of the pharmacological experiments were performed *in vivo/ex vivo*.





- Pharmacological effects were observed at the organism's level that led to the potential variety of molecular mechanisms of action.

## PASS: Development & Updating Workflow





# Both Chemical and Biological Data Must be Curated



Alex Tropsha

Muratov, Fourches, Tropsha. Trust but verify. *J. Chem. Inf. Model.* **2010**, 50:1189-1204.

Fourches, Muratov, Tropsha. *Nat Chem Biol.* **2015**, 11:535.

Fourches, Muratov, Tropsha. Trust but verify II. *J. Chem. Inf. Model.* **2016**, 56:1243.

# PharmaExpert: Interpretation of the predictions




Alexey Lagunin

The screenshot displays the PharmaExpert software interface. At the top, there is a menu bar (File, Tools, View, Help) and a toolbar. Below this is a window titled "Prediction & Interpretation - H:\DATABASES\DRUG-BANK\Approved (PASS2014).SDF. 57/1278". The main area shows chemical structures for several compounds: Cholecalciferol, Menadione, Adenosine triphosphate, L-Proline, Adenine, L-Asparagine, Pravastatin, Fluvoxamine, Valsartan, Ramipril (highlighted in blue), and Masoprocol. Below the structures is a table with columns for Pa, Pi, and Activity. The table lists various activities such as "Abdominal distension", "Toxic, vascular", "Diuretic", "Excitability", "Dry eye", "Gluconate 2-dehydrogenase (acceptor) inhibitor", "Dermatomyositis", "Vasodilator", "Inflammation", "Gynaecomastia", "Scleroderma", "Diplopia", "Induration", "Atrial natriuretic peptide agonist", "Stevens-Johnson syndrome", "Dyspnea", "Swelling", "QT interval prolongation", "Immunotoxin", "Anemia", "Breast pain", "Angioedema", "Carcinogenic, mouse, female", "Vasodilator, coronary", "Hemochromatosis", "TGFβ1 expression inhibitor", "Stridor", "Taste disturbance", "Psychostimulant", and "Antihypertensive". The "Antihypertensive" activity is highlighted in blue. To the right of the table is a section for "Predicted value descending" and "Show non predicted activities". Below this is a table with columns for UniProt ID, Gene name(s), and Species. The bottom right corner shows a search and filter interface with "Add", "Search", "Delete", "Clear", "Load", "Include", and "Save" buttons.


Poroikov V. et al. In: *QSAR and Molecular Modelling in Rational Design of Bioactive Molecules*. Ankara, CADD & D Society, **2005**, p.514.  
Lagunin A. et al. Chemo- and bioinformatics resources for in silico drug discovery from medicinal plants beyond their traditional use: a critical review.. *Nat. Prod. Rep.*, **2014**, *31*: 1585.



# GUSAR: General Unrestricted Structure-Activity Relationships



Alexey Zakharov





## Our Software Registration by the Russian State Patent Agency

**METAPREDICT**

**No. 2004610666 of 12.03.2004**

**PASS**

**No. 2006613275 of 15.09.2006**

**PreTox**

**No. 2006613276 of 15.09.2006**

**PharmaExpert**

**No. 2006613590 of 16.10.2006**

**GUSAR**

**No. 2006613591 of 16.10.2006**

**BIOGENPHARM**

**No. 2006614395 of 15.02.2007**

**BIOGENERATOR**

**No. 2006614396 of 15.02.2007**

**NetFlowEx**

**No. 2011617330 of 26.05.2011**

**Net2Target**

**No. 2014660877 of 17.10.2014**

**PASS CLC Pred**

**No. 2016610382 of 11.01.2016**

**PASS Targets**

**No. 2016610846 of 20.01.2016**

**PASS SMP**

**No. 2016663627 of 13.11.2016**





# Our freely available predictive web-services



Dmitry Druzhilovskiy



Anastassia Rudik

The screenshot shows the Way2Drug website interface. At the top, there is a navigation bar with links for HOME, ABOUT, SERVICES, ACTIVITIES, PUBLICATIONS, and RESULTS. A 'LOGIN' link is also present for users with accounts. The 'SERVICES' menu is open, displaying a list of 20 predictive web services. A yellow box highlights the text '20 predictive web services'. Below the menu, there are three main content blocks: 'Global research', 'Referential id', and 'Collaboration'. The 'Global research' block describes the discovery of new safe and potent medicines. The 'Referential id' block discusses the integration of current biomedical and chemical knowledge. The 'Collaboration' block provides a framework for effective interaction of researchers.

Service Name
Predictors
Databases
SAR Creator
PASS Online Total
PASS Online Selector
MNA/QNA Similarity
FDA PCP Search
MPDS Search
PASS Online
PASS Targets
KinScreen
DIGEP-Pred
PASS CLC Pred
AntiHIV-Pred
AntiBac-Pred
SOMP: Sites of Metabolism Prediction
SMP: Substrate/Metabolite Specificity Prediction
RA: Reacting Atoms
MetaTox
Acute rat toxicity
Antitarget prediction
Ecotoxicity
ROSC-Pred
ADVER-Pred
DDI-Pred
Resistance
SprOS



**EEV CONGRESS**  
and applied chemistry  
**September 9th - 13th, 2019.**



### Global research

Discovery of new safe and potent medicines based on cutting-edge knowledge of a certain pathology at the molecular, cellular, tissue and organism levels, and the most promising pharmacological targets.



### Referential id

Integration of the current biomedical and chemical knowledge, extraction of the useful information and generation of new ideas in the field of chemical-biological interactions.



### Collaboration

Providing framework for effective interaction of researchers working in the multidisciplinary field of drug design & discovery, to combine their complementary background, knowledge, experience and facilities.

# PASS, PharmaExpert and GUSAR: Some Applications

Drug Discovery Today • Volume 00, Number 00 • August 2015

REVIEWS

Teaser *In silico* approaches reveal mechanisms of adverse drug reactions and predict them at the earliest stages of drug development.

**In silico assessment of adverse drug reactions and associated mechanisms**

Reviews • KEYNOTE REVIEW

Sergey M. Ivanov<sup>1,2</sup>, Alexey A. Lagunin<sup>1,2</sup> and Vladimir V. Poroikov<sup>1,2</sup>

<sup>1</sup>Institute of Biomedical Chemistry, 10/8, Pogodinskaya Str., Moscow, 119121, Russia  
<sup>2</sup>Pirogov Russian National Research Medical University, 117997 Moscow, Russia

During recent years, various *in silico* approaches have been used to estimate chemical and biological features of drug fragments, protein targets, and adverse drug reactions (ADRs). These features have also been used to predict the development of ADRs. In this review, we discuss the use of *in silico* approaches to predict these features for a certain class of drugs.

JOURNAL OF CHEMICAL INFORMATION AND MODELING

Application Note

pubs.acs.org/jcim

## MetaTox: Web Application for Predicting Structure and Toxicity of Xenobiotics' Metabolites

Anastasia V. Rudik,<sup>\*,†</sup> Vladislav M. Bezhentsev,<sup>†</sup> Alexander V. Dmitriev,<sup>†</sup> Dmitry S. Druzhilovskiy,<sup>†</sup> Alexey A. Lagunin,<sup>\*,‡</sup> Dmitry A. Filimonov,<sup>†</sup> and Vladimir V. Poroikov<sup>†</sup>

Chemical Research in Toxicology

Article

pubs.acs.org/crt

## Quantitative Prediction of Antitarget Interaction Profiles for Chemical Compounds

Alexey V. Zakharov,<sup>\*,†,‡</sup> Alexey A. Lagunin,<sup>‡</sup> Dmitry A. Filimonov,<sup>‡</sup> and Vladimir V. Poroikov<sup>‡</sup>

<sup>†</sup>National Science Institute, National Institute of Health, Bethesda, Maryland, United States  
<sup>‡</sup>Department of Chemistry, National Institute of Health, Bethesda, Maryland, United States

DE GRUYTER

Drug Metabol Pers Ther 2018; 33(2): 65–73

Dmitriy V. Ivashchenko\*, Anastasia V. Rudik, Andrey A. Poloznikov, Sergey V. Nikulin, Valeriy V. Smirnov, Alexander G. Tonevitsky, Eugeny A. Bryun and Dmitriy A. Sychev

## Which cytochrome P450 metabolizes phenazepam? Step by step *in silico*, *in vitro*, and *in vivo* studies

Лабораторные животные для научных исследований

Научно-практический журнал. eISSN 2618723X / DOI 10.29296/2618723X


Russian English

## Альтернативные методы исследования. Компьютерная оценка острой токсичности для грызунов

В.С. Сухачев<sup>1,2</sup>, лаборант Института биологической химии им. М.В. Ломоносова, С.М. Иванов<sup>1</sup>, канд. биол. наук, науч. сотрудник, В.Н. Ореховича, ORCID ID: 0000-0002-0339-8478, Д.А. Филимонов<sup>1</sup>, канд. физ.-мат. наук, В.В. Пороиков<sup>1</sup>, профессор, д-р биол. наук, В.Н. Ореховича, заведующий лабораторией, 119121, Москва, Погодинская ул., 10/8, Россия

1 Научно-исследовательский институт биологической химии им. М.В. Ломоносова, Москва, 119121, Россия  
 2 Российский технологический университет, Москва, пр-т Вернадского, 119571, Россия

E-mail: withstanding@yandex.ru



Резюме

Определение значений полуколичественных индексов токсичности (TL<sub>50</sub>) для 4 способов введения веществ с использованием компьютерной версии (для крыс и мышей), та...

Chem Soc Rev

REVIEW ARTICLE

Check for updates

## QSAR without borders

Eugene N. Muratov,<sup>id</sup> Jürgen Bajorath,<sup>id</sup> Robert P. Sheridan,<sup>id</sup> Igor V. Tetko,<sup>id</sup> Dmitry Filimonov,<sup>id</sup> Vladimir Poroikov,<sup>id</sup> Tudor I. Oprea,<sup>id</sup> Igor I. Baskin,<sup>id</sup> Alexandre Varnek,<sup>id</sup> Adrian Roitberg,<sup>id</sup> Olexandr Isayev,<sup>id</sup> Stefano Curtalolo,<sup>id</sup> Denis Fourches,<sup>id</sup> Yoram Cohen,<sup>id</sup> Alan Aspuru-Guzik,<sup>id</sup>

Cite this: DOI: 10.1039/d0cs00098a

View Article Online  
View Journal

ehp Environmental Health Perspectives

OPEN ACCESS

HOME CURRENT ISSUE ARCHIVES COLLECTIONS 中文翻译 AUTHORS ABOUT

Vol. 128, No. 2 | Research

## CoMPARA: Collaborative Modeling Project for Androgen Receptor Activity

Kamel Mansouri, Nicole Kleinstreuer, Ahmed M. Abdelaziz, Domenico Alberga, Vinicius M. Alves, Patrik L. Andersson, Carolina H. Andrade, Fang Bai, Ilya Balabin, Davide Ballabio, Emilio Benfenati, Barun Bhatnagar, Scott Boyer, Jingwen Chen, Viviana Consonni, Sherif Farag, Denis Fourches, Alfonso T. García-Sosa, Paola Gramatica, Francesca Grisoni, Chris M. Grulke, Huixiao Hong, Dragos Horvath, Xin Hu, Ruili Huang, ... See all authors

Published: 7 February 2020 | CID: 027002 | https://doi.org/10.1289/EHP5580

Sections PDF Supplemental Materials Tools Share

Abstract

**Background:** Endocrine disrupting chemicals (EDCs) are xenobiotics that mimic the interaction of natural hormones and alter synthesis, transport, or metabolic pathways. The prospect of EDCs causing adverse health effects in humans and wildlife has led to the development of scientific and regulatory approaches for evaluating bioactivity. This need is being addressed using high-throughput screening (HTS) *in vitro* approaches and computational modeling.

# Could we estimate *in silico* which drug is not safe enough?




Predicts ~500 adverse and toxic effects


$$\text{Toxicity Index (TI)} = \sum N_{adv\&tox}$$

For 88% of 276 withdrawn drugs TI exceeds the Threshold.

Average TI values for drugs launched each five years



Threshold value: TI = 108



For Fenspiride TI = 293; threshold exceeded by more than twice.



## Summary and further prospects

- ✓ Based on our long-term studies in bio- and chemoinformatics, we developed general computational methods predicted with reasonable accuracy many biological activities/properties using structural formula of drug-like compound as an input data.
- ✓ We developed 20 web-services that are widely used by about 24 thousand researchers from 100 countries; more than 800 independent papers published with the appropriate citations.
- ✓ Further development of these resources requires integration, curation of the information, improvement of functionality, etc.
- ✓ Active cooperation between the researchers working in the field of drug discovery will be beneficial for all parties.



# Acknowledgements

## Our current team

Dmitry Filimonov, Tatyana Glorizova,  
 Alexey Lagunin, Dmitry Druzhilovskiy,  
 Anastasia Rudik, Alexander Dmitriev,  
 Olga Tarasova, Alexander Veselovsky,  
 Boris Sobolev, Oleg Gomazkov,  
 Sergey Ivanov, Pavel Pogodin, Leonid Stolbov,  
 Dmitry Karasev, Polina Savosina, Nikita Ionov,  
 Nadezhda Biziukova

## Former team members

Yulia Borodina, Alexey Zakharov,  
 Varvara Dubovskaja, Anastassia Sergeiko,  
 Alexandra Urusova, Khalimat Murtazalieva,  
 Vladislav Bezhentsev, Maxim Semin

## Some our collaborators

Athina Geronikaki (Greece), Marc Nicklaus (USA),  
 Rajesh Goel (India), Alexander Kel (Germany),  
 Alexandre Varnek (France), Valery Dembitsky  
 (Canada), Narahari Sastry (India), . . .



# Thank you for your kind attention!

Your questions, please, address to: [vladimir.poroikov@ibmc.msk.ru](mailto:vladimir.poroikov@ibmc.msk.ru); [vvp1951@yandex.ru](mailto:vvp1951@yandex.ru)

**Vladimir Poroikov**

Institute of Biomedical Chemistry  
Verified email at ibmc.msk.ru - [Homepage](#)  
Bioinformatics Chemoinformatics Computer-Aided Drug Disco...


**Cited by** [VIEW ALL](#)

	All	Since 2015
Citations	6952	4027
h-index	42	33
i10-index	118	91

**Co-authors** [EDIT](#)

- Lagunin Alexey  
Институт биомедицинской хими...
- Alexey Zakharov  
National Institutes of Health
- Valery M Dembitsky  
Lethbridge College
- Prof. Rajesh Kumar Goel  
Professor and Dean Faculty of M...
- Dmitry Druzhilovsky  
Institute of Biomedical Chemistry...

TITLE	CITED BY	YEAR
<a href="#">PASS: prediction of activity spectra for biologically active substances</a> A Lagunin, A Stepanchikova, D Filimonov, V Poroikov Bioinformatics 16 (8), 747-748	454	2000
<a href="#">Robustness of biological activity spectra predicting by computer program PASS for noncongeneric sets of chemical compounds</a> VV Poroikov, DA Filimonov, YV Borodina, AA Lagunin, A Kos Journal of chemical information and computer sciences 40 (6), 1349-1355	303	2000
<a href="#">Prediction of the biological activity spectra of organic compounds using the PASS online web resource</a> DA Filimonov, AA Lagunin, TA Glorizova, AV Rudik, DS Druzhilovskii, ... Chemistry of Heterocyclic Compounds 50 (3), 444-457	282	2014
<a href="#">PASS biological activity spectrum predictions in the enhanced open NCI database browser</a> VV Poroikov, DA Filimonov, WD Ihlenfeldt, TA Glorizova, AA Lagunin, ... Journal of chemical information and computer sciences 43 (1), 228-236	228	2003
<a href="#">QSAR modelling of rat acute toxicity on the basis of PASS prediction</a> A Lagunin, A Zakharov, D Filimonov, V Poroikov Molecular informatics 30 (2-3), 241-250	209	2011
<a href="#">Chemical similarity assessment through multilevel neighborhoods of atoms: definition and comparison with the other descriptors</a> D Filimonov, V Poroikov, Y Borodina, T Glorizova Journal of chemical information and computer sciences 39 (4), 666-670	203	1999



List of our publications: <https://scholar.google.ru/citations?user=F13hIJMAAAAJ&hl=en>

Citation Map: <https://publons.com/dashboard/tools/citation-map/>